对针对血管疾病炎症的药物进行叙述性审查
Jenna Kristan1, Mark A Malesker1, James M Backes2
1Department of Pharmacy Practice, Creighton University School of Pharmacy and Health, Omaha, NE, USA.
Postgraduate medicine
|October 6, 2025
概括
针对心血管疾病中的炎症显示出混合的结果. 虽然一些特定的抗炎药物提供了好处,但需要进一步的研究,以有效地减少残留心血管风险.
科学领域:
- 心血管医学 心血管医学
- 炎症研究 炎症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症是动脉样硬化的一个关键因素,增加心肌梗塞和中风的风险.
- 过去针对心血管 (CV) 疾病的抗炎药物试验产生了不一致的结果.
- 类固醇可以通过除抗炎症之外的机制来降低心血管风险.
研究的目的:
- 审查抗炎策略在控制心血管疾病中的演变作用.
- 评估针对特定炎症途径的各种抗炎药物的疗效.
- 了解利用炎症作为降低心血管风险的目标的挑战.
主要方法:
- 对心血管风险的抗炎药物进行历史和最近研究的审查.
- 针对广泛与特定炎症途径 (例如,NLRP3炎症体,IL-1β,IL-6) 的药物的分析.
- 对诸如皮质类固醇,甲状腺素和胆固醇等药物的结局结果的检查.
主要成果:
- 广泛的抗炎药物 (皮质类固醇,甲铁酸) 没有显示CV益处.
- 针对NLRP3炎症酶,IL-1β/IL-6和hs-CRP的特定药物已经显示出治疗前景.
- 最近关于胆固醇的数据引发了关于其常规CV风险降低使用的不确定性.
结论:
- 有针对性的抗炎方法对于显著减少心血管事件至关重要.
- 我们对心血管风险炎症管理的理解落后于高血压和脂质失调.
- 目前正在进行的研究探索抗细胞因子剂以解决残留心血管风险.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490
Inflammatory Response I: Vascular and Cellular
16.0K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
16.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456


